Theravance Biopharma (FRA:0TB) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
71 GF Score
Price €14.50
GF Value €14.63
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Theravance Biopharma Defensive Interval Ratio?

FRA:0TB
71GF Score
Theravance Biopharma Inc FRA:0TB
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.50 is trading 0.9% below its estimated GF Value™ of €14.63. GuruFocus considers Theravance Biopharma to be Fairly Valued.

Key valuation signals for FRA:0TB:

  • Defensive Interval Ratio:
  • GF Value™: €14.63 vs. price of €14.50 (0.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
71GF Score

Get the complete analysis for FRA:0TB

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.50
Price
€14.63
GF Value